Two of the fastest -moving 100 Barchart stakes you can buy on Monday’s trade were Kopin (Kopn) and nephros (nef), 60 and 52, respectively, descended in the 40s and 48th positions.
I will be honest, I have never heard of any of these companies, but they are moving fast, and this is the only thing that is important at this time.
Kopin’s Stock increased by 62%in the last month, and in 2025. – 163%, entering the list in a higher position than any other 14 new participants. Certainly, trade in USD is less than $ 5, and Penny’s shares are likely to increase the interest of retailing investors seeking fast profits.
I, on the other hand, want to buy and have a careful stock of the long distance; Promotions that business can grow for decades, not years.
As far as Nephrra is concerned, its shares reached a 52 week height of $ 5.59, which is the highest level of shares in three years. Over the past 36 months, its shares estimated 377%, and over the same period, the Copular Returns outdoors.
Today, my task is to determine whether any stock has the necessary things to move to two digits and beyond for the next three – five years.
The 41 -year -old Massachusetts business specializes in Microdisplay technology and optical systems.
“These products are very important for programs, ranging from weap mounted thermal sights to spatial calculations and medical headphones,” the 2024 10-K said.
“We have been supplying our Microdissplays and Asos to the US Department of Defense for soldiers, Rotary and” Fixed Wings for Aircraft “for many years and developing products for armored vehicles and soldiers for rocket systems.”
2024. 82% of its $ 50.3 million. USD revenue was received by customers in the defense industry. This increased from 56% 2023. And 52% 2022.
There is nothing wrong with concentrating your business on defense customers. Huntington Ingals Industries (HII) It does, and its shares increased by 53%a year. It is a dangerous world. Someone has to produce products for soldiers.
The obvious risk is the concentration of customers. The two best accounted for 76% of its 2024. The LLC is the highest – 65%of the revenue with the LLC of LLC.
The good news is that the DRS is a subsidiary of Leonardo DRS (DRS), a company with a $ 12 billion market worth of market, which in turn; (Finmy)Italian Defense Conglomerate with a $ 37 billion market in the market. Copin does not have to worry about salary.
One of the risks to buy Kopin’s shares for a long trip is the consistency of income and income growth. Over the years, there is one thing to experience EBB and flows, but this company has never been able to transfer the highest revenue over $ 115 million. USD (2008 and 2009).
According to S&P Global Market Intelligence, its income has ranged from 64.7 million over the last 15 years. USD in 2011, on the high side, and in 2016 – $ 22.6 million.
Finally, in the last 35 years, he has earned annual activity profit only four times. As a result, the accumulated deficit is $ 410 million. USD. It would take decades to eliminate this deficit.
The company has just completed $ 41 million. USD pipe (private investment in public capital) to continue the latest growth plans. Based on August $ 162.8 million Shares, the pipe reduced the shareholders by 12%.
Pipe investors bought shares for $ 2.10 for a share to protect their interests. It had little to do because the Copin was a great investment.
I will not buy the Kopn stock on the long -distance road. However, the volume of options is appropriate, so if you have, it may be a good idea to consider using the call options to make your own bet.
The manufacturer of water filtration products for medical and commercial markets is significantly smaller than the Copin, with only 61 million. USD with the help of the micro-kap area. This is not necessarily a bad thing.
1997 Founded by medical professionals related to the Columbia University Medical Center and New York Hospital in New York, the company is directed at four markets: hospitals and other health care facilities, dialysis centers, commercial institutions and military and outdoor recreation.
During the first six 2025 For months, its income amounted to $ 9.3 million.
She has now created three consecutive quarters of profitability. He finished in the second quarter when 12 months’ income was $ 16.7 million. USD, 21% higher than the same period a year ago.
The most important basis for its profitability is the increase in total profit margins. 2025 In the second quarter, this rate was 63%, 400 base points greater than 2024. In the second quarter.
From the balance sheet perspective, the second quarter ended $ 5.1 million. USD cash and no debt.
Nephra has publicly announced in 2004. September For $ 6.00 per share. Since 1997 April He earned only $ 300,000 in revenue, while spending more than $ 12.5 million. USD research and development.
2004 June 30 The deficit accumulated in it was $ 30.9 million. USD. From 2025 June 30 The deficit increased to 143.5 million. USD.
The difference between Nephros and the copy is that the former business business actually turns the corner.
2015 The company reported $ 1.94 million. USD revenue and operating losses are $ 3.25 million. USD. Within 12 months, its income was $ 16.68 million on June 3. USD, and operating profits were $ 1.34 million. USD.
Most importantly, Nephra shareholders have increased income in six out of the last 10 years and 8% of the activity margin in 12 months.
I don’t think the question arises as to whether to buy and keep investors better with Nephros rather than Copin. It is better from the top 100 shares.
On the day of the publication, Will Ashworth had no (directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article are only for information purposes. This article was originally published in barchart.com
